NO20045276L - Heteroarylforbindelser som inhiberer leukocyttadhesjon formidlet ved alfa-4-integriner - Google Patents

Heteroarylforbindelser som inhiberer leukocyttadhesjon formidlet ved alfa-4-integriner

Info

Publication number
NO20045276L
NO20045276L NO20045276A NO20045276A NO20045276L NO 20045276 L NO20045276 L NO 20045276L NO 20045276 A NO20045276 A NO 20045276A NO 20045276 A NO20045276 A NO 20045276A NO 20045276 L NO20045276 L NO 20045276L
Authority
NO
Norway
Prior art keywords
sub
alpha
integrins
compounds
leukocyte adhesion
Prior art date
Application number
NO20045276A
Other languages
English (en)
Norwegian (no)
Inventor
Eugene D Thorsett
Michael A Pleiss
Christopher M Semko
Andrei W Konradi
Ying-Zi Xu
Frank Stappenbeck
Brian P Stupi
Jenifer Smith
Original Assignee
Elan Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharm Inc filed Critical Elan Pharm Inc
Publication of NO20045276L publication Critical patent/NO20045276L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50—Three nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20045276A 2002-05-24 2004-12-01 Heteroarylforbindelser som inhiberer leukocyttadhesjon formidlet ved alfa-4-integriner NO20045276L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38324402P 2002-05-24 2002-05-24
PCT/US2003/017150 WO2003099231A2 (fr) 2002-05-24 2003-05-27 Composes heteroaryle inhibant l'adhesion leucocytaire induite par des integrines alpha-4

Publications (1)

Publication Number Publication Date
NO20045276L true NO20045276L (no) 2004-12-01

Family

ID=29584533

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20045276A NO20045276L (no) 2002-05-24 2004-12-01 Heteroarylforbindelser som inhiberer leukocyttadhesjon formidlet ved alfa-4-integriner

Country Status (17)

Country Link
US (2) US7335663B2 (fr)
EP (1) EP1507533B1 (fr)
JP (1) JP4413135B2 (fr)
CN (1) CN1311829C (fr)
AT (1) ATE464298T1 (fr)
AU (1) AU2003237302B8 (fr)
BR (1) BR0309619A (fr)
CA (1) CA2480756A1 (fr)
DE (1) DE60332109D1 (fr)
EA (1) EA008180B1 (fr)
IL (1) IL164323A (fr)
MX (1) MXPA04011657A (fr)
NO (1) NO20045276L (fr)
NZ (1) NZ535723A (fr)
TW (1) TW200307671A (fr)
WO (1) WO2003099231A2 (fr)
ZA (1) ZA200407944B (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2339738T3 (es) * 1999-01-22 2010-05-25 Elan Pharmaceuticals, Inc. Derivados de acilo los cuales tratan trastornos relacionados con vla-4.
CA2528723A1 (fr) * 2003-06-25 2005-01-06 Elan Pharmaceuticals, Inc. Methodes et compositions de traitement de la polyarthrite rhumatoide
JP2007528397A (ja) * 2004-03-10 2007-10-11 メルク　エンド　カムパニー　インコーポレーテッド Ｖｌａ−４アンタゴニスト
NZ588839A (en) * 2004-07-08 2012-09-28 Elan Pharm Inc Multivalent vla-4 antagonists comprising polyethylene glycol moieties
BRPI0514415A (pt) * 2004-08-16 2008-06-10 Merck & Co Inc composto, composição farmacêutica, e, uso de um composto
CA2851103A1 (fr) * 2005-09-29 2007-04-12 Elan Pharmaceuticals, Inc. Composes de pyrimidinyl amide qui inhibent l'adherence leucocytaire a mediation par vla-4
NZ567270A (en) * 2005-09-29 2011-06-30 Elan Pharm Inc Pyrimidinyl amide compounds which inhibit leukocyte adhesion mediated by VLA-4
KR20080100271A (ko) * 2006-02-27 2008-11-14 엘란 파마슈티칼스, 인크. Ｖｌａ-4에 의해 매개되는 백혈구 부착을 억제하는 피리미디닐 술폰아미드 화합물
US20070207141A1 (en) * 2006-02-28 2007-09-06 Ivan Lieberburg Methods of treating inflammatory and autoimmune diseases with natalizumab
CA2641160A1 (fr) * 2006-02-28 2007-09-07 Elan Pharmaceuticals, Inc. Methodes pour traiter des maladies inflammatoires et auto-immunes avec des composes inhibiteurs alpha-4
JP5504390B2 (ja) 2006-03-03 2014-05-28 バイオジェン・アイデック・エムエイ・インコーポレイテッド ナタリズマブを用いて炎症性疾患及び自己免疫疾患を治療する方法
EP2231185A4 (fr) * 2007-12-07 2012-06-27 Elan Pharm Inc Procédés et compositions pour traiter des tumeurs liquides
EP2424841A1 (fr) * 2009-04-27 2012-03-07 Elan Pharmaceuticals Inc. Antagonistes à base de pyridinone d'intégrines alpha-4
US11287423B2 (en) 2010-01-11 2022-03-29 Biogen Ma Inc. Assay for JC virus antibodies
PL2524060T3 (pl) 2010-01-11 2018-05-30 Biogen Ma Inc. Test wykrywający przeciwciała przeciwko wirusowi jc
US8343706B2 (en) 2010-01-25 2013-01-01 International Business Machines Corporation Fluorine-free fused ring heteroaromatic photoacid generators and resist compositions containing the same
EP3004334A4 (fr) 2013-05-28 2016-12-21 Biogen Ma Inc Méthodes d'évaluation de risque de développement d'une lemp
EP3810085A1 (fr) 2018-06-20 2021-04-28 Progenity, Inc. Traitement d'une maladie du tractus gastro-intestinal par un inhibiteur de l'intégrine
CA3114240C (fr) 2018-10-30 2023-09-05 Gilead Sciences, Inc. Derives d'imidazopyridine utilises en tant qu'inhibiteurs de l'integrine alpha4beta7
WO2020092401A1 (fr) 2018-10-30 2020-05-07 Gilead Sciences, Inc. COMPOSÉS POUR INHIBITION DE L'INTÉGRINE ALPHA 4β7
US11224600B2 (en) 2018-10-30 2022-01-18 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
EP3873884A1 (fr) 2018-10-30 2021-09-08 Gilead Sciences, Inc. Dérivés de quinoléine utilisés en tant qu'inhibiteurs de l'intégrine alpha4bêta7
CN111197057B (zh) * 2018-11-19 2024-04-19 中国科学院分子细胞科学卓越创新中心 调控免疫细胞迁移的组合物和方法
JP7491996B2 (ja) 2019-08-14 2024-05-28 ギリアード サイエンシーズ， インコーポレイテッド α４β７インテグリンの阻害のための化合物

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2525656A1 (de) 1974-06-19 1976-01-15 Sandoz Ag Verfahren zur herstellung neuer heterocyclischer verbindungen
US4073914A (en) 1974-11-08 1978-02-14 Mitsubishi Chemical Industries Limited N2 -naphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US4041156A (en) 1974-11-08 1977-08-09 Mitsubishi Chemical Industries Limited N2 -alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US4018915A (en) 1976-01-05 1977-04-19 Mitsubishi Chemical Industries Ltd. N2 -alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US4046876A (en) 1974-11-08 1977-09-06 Mitsubishi Chemical Industries Limited N2 -alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US4070457A (en) * 1974-11-08 1978-01-24 Mitsubishi Chemical Industries Ltd. N2 -naphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US4104392A (en) * 1974-11-08 1978-08-01 Mitsubishi Chemical Industries Ltd. N2 -naphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof, and antithrombotic compositions and methods employing them
US4055651A (en) 1974-11-08 1977-10-25 Mitsubishi Chemical Industries Ltd. N2 -alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US4096255A (en) * 1974-11-08 1978-06-20 Mitsubishi Chemical Industries Limited N2 -naphthalenesulfonyl-L-argininamides, and pharmaceutical salts, compositions and methods
US4055636A (en) * 1974-11-08 1977-10-25 Mitsubishi Chemical Industries Ltd. N2 -alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
JPS5727454B2 (fr) * 1975-02-21 1982-06-10
CA1102316A (fr) 1975-12-09 1981-06-02 Shosuke Okamoto Traduction non-disponible
US4018913A (en) 1976-01-14 1977-04-19 Mitsubishi Chemical Industries Ltd. N2 -alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US4036955A (en) * 1976-07-22 1977-07-19 Mitsubishi Chemical Industries Ltd. N2 -naphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
DE2742173A1 (de) * 1977-09-20 1979-03-29 Bayer Ag Phenoxy-pyridinyl(pyrimidinyl)-alkanole, verfahren zu ihrer herstellung sowie ihre verwendung als fungizide
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
IT1211096B (it) 1981-08-20 1989-09-29 Lpb Ist Farm Pirimidine e s.triazinici adattivita' ipolipidemizzante.
US4672065A (en) 1982-11-19 1987-06-09 Chevron Research Company N-substituted phenoxyacetamide fungicides
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4565814A (en) 1983-01-28 1986-01-21 Sanofi Pyridazine derivatives having a psychotropic action and compositions
JPS59212480A (ja) 1983-05-17 1984-12-01 Nippon Soda Co Ltd ピリダジン誘導体及び除草剤
DE3322720A1 (de) * 1983-06-24 1985-01-03 Chemische Werke Hüls AG, 4370 Marl Verwendung von in 2-stellung mit (substituierten) aminogruppen substituierten 4-dl-alkylester-(alpha)-alaninyl-6-chlor-s-triazinen als herbizide, insbesondere gegen flughafer
US4505910A (en) * 1983-06-30 1985-03-19 American Home Products Corporation Amino-pyrimidine derivatives, compositions and use
NZ210669A (en) 1983-12-27 1988-05-30 Syntex Inc Benzoxazin-4-one derivatives and pharmaceutical compositions
PH22520A (en) 1984-11-12 1988-10-17 Yamanouchi Pharma Co Ltd Heterocyclic compounds having 4-lover alkyl-3-hydroxy-2-lower alkyl phenoxy-lower alkylene-y-group, and process of producing them
US4959364A (en) * 1985-02-04 1990-09-25 G. D. Searle & Co. Method of treating inflammation, allergy, asthma and proliferative skin disease using heterocyclic amides
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4837028A (en) * 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
JPH0784424B2 (ja) 1987-04-15 1995-09-13 味の素株式会社 チロシン誘導体及びその用途
EP0330506A3 (fr) * 1988-02-26 1990-06-20 Dana Farber Cancer Institute Protéines VLA
DE3904931A1 (de) * 1989-02-17 1990-08-23 Bayer Ag Pyridyl-substituierte acrylsaeureester
US5030644A (en) * 1989-07-31 1991-07-09 Merck & Co., Inc. Imidazole compounds and their use as transglutaminase inhibitors
US5260210A (en) 1989-09-27 1993-11-09 Rubin Lee L Blood-brain barrier model
US4992439A (en) 1990-02-13 1991-02-12 Bristol-Myers Squibb Company Pyridazine carboxylic acids and esters
FR2679903B1 (fr) 1991-08-02 1993-12-03 Elf Sanofi Derives de la n-sulfonyl indoline portant une fonction amidique, leur preparation, les compositions pharmaceutiques en contenant.
NZ239846A (en) 1990-09-27 1994-11-25 Merck & Co Inc Sulphonamide derivatives and pharmaceutical compositions thereof
DE4108029A1 (de) 1991-03-13 1992-09-17 Bayer Ag Triazinyl-substituierte acrylsaeureester
AU1354292A (en) 1991-03-18 1992-10-21 Pentapharm Ag Parasubstituted phenylalanine derivates
IT1247509B (it) 1991-04-19 1994-12-17 Univ Cagliari Composti di sintesi atti all'impiego nella terapia delle infezioni da rhinovirus
US5296486A (en) 1991-09-24 1994-03-22 Boehringer Ingelheim Pharmaceuticals, Inc. Leukotriene biosynthesis inhibitors
AU3420693A (en) 1991-12-24 1993-07-28 Fred Hutchinson Cancer Research Center Competitive inhibition of high-avidity alpha4-beta1 receptor using tripeptide ldv
NZ249789A (en) * 1992-03-11 1997-07-27 Narhex Ltd Hydrazine, carbazate and 1,2-diazacyclic derivatives and pharmaceutical compositions
DE4227748A1 (de) 1992-08-21 1994-02-24 Bayer Ag Pyridyloxy-acrylsäureester
JP2848232B2 (ja) 1993-02-19 1999-01-20 武田薬品工業株式会社 アルデヒド誘導体
US5770573A (en) * 1993-12-06 1998-06-23 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
TW574214B (en) * 1994-06-08 2004-02-01 Pfizer Corticotropin releasing factor antagonists
US5510332A (en) * 1994-07-07 1996-04-23 Texas Biotechnology Corporation Process to inhibit binding of the integrin α4 62 1 to VCAM-1 or fibronectin and linear peptides therefor
JPH10506608A (ja) 1994-07-11 1998-06-30 アセナ ニューロサイエンシーズ，インコーポレイテッド 白血球接着のインヒビター
US6306840B1 (en) 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
IL117659A (en) 1995-04-13 2000-12-06 Dainippon Pharmaceutical Co Substituted 2-phenyl pyrimidino amino acetamide derivative process for preparing the same and a pharmaceutical composition containing same
AU702487B2 (en) * 1995-08-30 1999-02-25 G.D. Searle & Co. Meta-guanidine, urea, thiourea or azacyclic amino benzoic acid derivatives as integrin antagonists
CZ288178B6 (en) 1995-09-29 2001-05-16 Sankyo Co Milbemycin-5-oxime derivatives substituted in position 13-, and their use
DE19536891A1 (de) 1995-10-04 1997-04-10 Basf Ag Neue Aminosäurederivate, ihre Herstellung und Verwendung
DE19548709A1 (de) 1995-12-23 1997-07-03 Merck Patent Gmbh Tyrosinderivate
PT910575E (pt) 1996-06-21 2003-02-28 Takeda Chemical Industries Ltd Lipossomas fusogenicos
JP2000516575A (ja) 1996-06-28 2000-12-12 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング インテグリンインヒビターとしてのフェニルアラニン誘導体
DE19629817A1 (de) * 1996-07-24 1998-01-29 Hoechst Ag Neue Imino-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
DE19647381A1 (de) * 1996-11-15 1998-05-20 Hoechst Ag Neue Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
DE19647317A1 (de) 1996-11-15 1998-05-20 Hoechst Schering Agrevo Gmbh Substituierte Stickstoff-Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel
HUP0000492A3 (en) 1996-11-22 2000-06-28 Lilly Co Eli N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
WO1998033783A1 (fr) 1997-02-04 1998-08-06 Versicor, Inc. Syntheses de banques combinatoires et de phases solides de 3,1-benzoxazine-4-ones
DE19713000A1 (de) 1997-03-27 1998-10-01 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
DE69833654T2 (de) 1997-05-29 2006-12-14 Merck & Co., Inc. (A New Jersey Corp.) Biarylalkansäuren in der verwendung als zelladhäsionsinhibitoren
CA2291778A1 (fr) 1997-05-29 1998-12-03 Merck & Co., Inc. Composes d'amide heterocycliques utilises en tant qu'inhibiteurs de l'adhesion cellulaire
KR20010022406A (ko) 1997-07-31 2001-03-15 진 엠. 듀발 Ｖｌａ-4에 의해 매개되는 백혈구 유착을 억제하는디펩타이드 및 관련 화합물
AR016133A1 (es) 1997-07-31 2001-06-20 Wyeth Corp Compuesto de carbamiloxi que inhiben la adhesion de leucocitos mediada por vla-4, compuestos que son prodrogas de dichos compuestos, composicionfarmaceutica, metodo para fijar vla-4 a una muestra biologica, metodo para el tratamiento de una condicion inflamatoria
CN1133648C (zh) 1997-07-31 2004-01-07 伊兰药品公司 抑制vla-4介导的白细胞粘附的取代的苯丙氨酸型化合物
AU8678698A (en) 1997-07-31 1999-02-22 American Home Products Corporation Compounds which inhibit leukocyte adhesion mediated by vla-4
HU229362B1 (en) 1997-08-22 2013-11-28 Hoffmann La Roche N-alkanoylphenylalanine derivatives
ES2214728T3 (es) 1997-08-22 2004-09-16 F. Hoffmann-La Roche Ag Derivados de n-aroilfenilalanina.
JP4564654B2 (ja) 1998-01-23 2010-10-20 ノバルティス アーゲー Ｖｌａ−４アンタゴニスト
US6329372B1 (en) 1998-01-27 2001-12-11 Celltech Therapeutics Limited Phenylalanine derivatives
CZ20003672A3 (cs) 1998-04-10 2001-08-15 G. D. Searle & Co. Heterocyklické glycyl-beta-alaninové deriváty jako agonisté vitronektinu
JP4753403B2 (ja) 1998-04-16 2011-08-24 エンサイシブ・フアーマシユーテイカルズ，インコーポレイテツド インテグリンのそのレセプターへの結合を阻害する化合物
GB9821061D0 (en) 1998-09-28 1998-11-18 Celltech Therapeutics Ltd Chemical compounds
GB9825652D0 (en) 1998-11-23 1999-01-13 Celltech Therapeutics Ltd Chemical compounds
WO2000043369A1 (fr) 1999-01-22 2000-07-27 Elan Pharmaceuticals, Inc. Composes inhibant l'adhesion aux leucocytes a mediation assuree par vla-4
ES2339738T3 (es) * 1999-01-22 2010-05-25 Elan Pharmaceuticals, Inc. Derivados de acilo los cuales tratan trastornos relacionados con vla-4.

Also Published As

Publication number Publication date
EA008180B1 (ru) 2007-04-27
CA2480756A1 (fr) 2003-12-04
DE60332109D1 (de) 2010-05-27
WO2003099231A3 (fr) 2004-01-22
AU2003237302A1 (en) 2003-12-12
TW200307671A (en) 2003-12-16
CN1652789A (zh) 2005-08-10
NZ535723A (en) 2005-08-26
EA200401561A1 (ru) 2005-06-30
EP1507533A4 (fr) 2007-05-23
EP1507533B1 (fr) 2010-04-14
AU2003237302B2 (en) 2008-03-06
US20050130999A1 (en) 2005-06-16
US7008949B2 (en) 2006-03-07
MXPA04011657A (es) 2005-08-18
BR0309619A (pt) 2005-06-28
US20040142954A1 (en) 2004-07-22
ATE464298T1 (de) 2010-04-15
AU2003237302B8 (en) 2008-04-03
IL164323A (en) 2010-02-17
WO2003099231A2 (fr) 2003-12-04
EP1507533A2 (fr) 2005-02-23
CN1311829C (zh) 2007-04-25
ZA200407944B (en) 2006-07-26
US7335663B2 (en) 2008-02-26
JP4413135B2 (ja) 2010-02-10
IL164323A0 (en) 2005-12-18
JP2005529155A (ja) 2005-09-29

Similar Documents

Publication Publication Date Title
NO20045276L (no) Heteroarylforbindelser som inhiberer leukocyttadhesjon formidlet ved alfa-4-integriner
DK1507775T3 (da) Heterocykliske forbindelser som hæmmer leukocyt-adhæsion medieret af alfa-4-integriner
TW200603788A (en) Multivalent vla-4 antagonists comprising polymer moieties
CA2290745A1 (fr) Composes de carbamyloxy inhibant une adhesion de leucocytes regulee par vla-4
MXPA01007335A (es) Derivados de acilo los cuales tratan trastornos relacionados con alfa4 beta1 integrina y cd49d/cd29 (vla-4).
BR9811569A (pt) Compostos que inibem a adesão de leucócito mediada por vla-4
DE602006019296D1 (de) Pyrimidinylamidverbindungen, die die durch vla-4 vermittelte leukozytenadhäsion inhibieren
MY151045A (en) Pyrimidinyl sulfonamide compounds which inhibit leukocyte adhesion mediated by vla-4
BR9812118A (pt) Compostos do tipo 4-amino-fenilalanina que inibem adesão de leucócito mediada por vla-4
WO2000043354A3 (fr) Composes inhibant l'adhesion leucocytaire provoquee par vla-4
WO2002008203A3 (fr) Derives de 3-(heteroaryl)alanine inhibiteurs de l'adherence des leucocytes provoquee par vla-4
ZA200803016B (en) Carbamate compounds which inhibit leukocyte adhesion mediated by VLA-4
WO2005111020A3 (fr) Analogues d’hydantoïne de pyrimidine qui empêchent l’adhésion des leucocytes par l’intermédiaire de vla-4
DE60009883D1 (de) Alpha-aminoessigsäure derivate als alpha 4 beta 7- rezeptor antagonisten
WO2000043371A3 (fr) Composes fusionnes cycliques heteroaryle et heteroaryle inhibant l'adhesion des leucocytes provoquees par vla-4
WO2002008201A3 (fr) Derives de l'acide beta-amino inhibiteurs de l'adhesion des leucocytes induite par vla-4
WO2000043413A3 (fr) Derives d'acide pyroglutamique et composes associes, inhibiteurs de l'adhesion leukocytaire a mediation de vla-4

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application